AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2013 by Medacta International SA
Sponsor:
Information provided by:
Medacta International SA
ClinicalTrials.gov Identifier:
NCT01107340
First received: April 15, 2010
Last updated: March 15, 2013
Last verified: March 2013

April 15, 2010
March 15, 2013
February 2010
February 2024   (final data collection date for primary outcome measure)
Assessment of the clinical outcome following total hip replacement using the Harris Hip Score [ Time Frame: 6 months after surgery ] [ Designated as safety issue: No ]
Assessment of patient improvement (subjective and objective) after surgery using the Harris Hip Score [ Time Frame: 6 months after surgery ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01107340 on ClinicalTrials.gov Archive Site
  • Assessment of the patient's physical level of activity using the Oxford Hip Score [ Time Frame: pre-op, annually post-op up to 10 years ] [ Designated as safety issue: No ]
  • Assessment of the improvement in quality of life and joint movement using the EuroQol-5D score [ Time Frame: pre-op, annually post-op up to 10 years ] [ Designated as safety issue: No ]
  • Assessment of implant survivorship as a measure of safety and tolerability [ Time Frame: 6 months, 3 years, 5 years, 7.5 years, 10 years after surgery ] [ Designated as safety issue: Yes ]
  • Assessment of the clinical outcome following total hip replacement using the Harris Hip Score [ Time Frame: pre-op, 6 months, 3 years, 5 years, 7.5 years, 10 years after surgery ] [ Designated as safety issue: No ]
  • Assessment of the patient's physical level of activity using the Oxford Hip Score [ Time Frame: pre-op, annually post-op up to 10 years ] [ Designated as safety issue: No ]
  • Assessment of the improvement in quality of life and joint movement using the EuroQol-5D score [ Time Frame: pre-op, annually post-op up to 10 years ] [ Designated as safety issue: No ]
  • Assessment of implant survivorship as a measure of safety and tolerability [ Time Frame: 6 months, 3 years, 5 years, 7.5 years, 10 years after surgery ] [ Designated as safety issue: Yes ]
  • Clinical assessment of patient using the Harris Hip Score [ Time Frame: pre-op, 6 months, 3 years, 5 years, 7.5 years, 10 years after surgery ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study
AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

This is a multicentre post-marketing prospective study to evaluate performance and clinical outcomes of AMIIStem primary hip system.

Not Provided
Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Osteoarthritis
  • Arthritis
  • Avascular Necrosis
  • Fracture of the Femoral Neck or Head
  • Congenital Hip Dysplasia
Device: AMIStem Hip System
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
February 2024
February 2024   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is a good candidate for a primary hip arthroplasty using AMIStem Hip System
  • Patient is willing and able to give informed consent to participate in the follow-up program
  • Patient is suitable for surgery and able to participate in the follow-up program.
  • Those presenting with disease that meets the indication for use for Medacta implants defined in the study (on-label use)

Exclusion Criteria:

  • Acute systemic or chronic infection
  • Skeletal immaturity
  • Severe muscular, neurological, vascular deficiency or other pathologies of the affected limb that may compromise the stability of the implant.
  • Bone condition that may compromise the stability of the implant.
  • Patient who are unwilling or unable to give consent, or to comply with the protocol and the follow-up program.
Both
Not Provided
No
Contact: Mara Colombo 0041 91 6966060 ext 011 colombo@medacta.ch
Switzerland,   United Kingdom
 
NCT01107340
P01.004.11
Not Provided
Not Provided
Medacta International SA
Not Provided
Principal Investigator: Richard E Field, PhD FRCS(Orth) British Orthopaedic Association
Medacta International SA
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP